Last updated: February 13, 2026
What is the drug identified by NDC 68462-0694?
NDC 68462-0694 corresponds to Ocrevus (ocrelizumab), a monoclonal antibody used primarily for multiple sclerosis (MS). It is approved by the FDA for relapsing-remitting MS (RRMS) and primary progressive MS (PPMS).
Market size and key drivers
Global multiple sclerosis market valued at approximately USD 23.5 billion in 2022, expected to grow at a compound annual growth rate (CAGR) of around 8% through 2030 (source: Grand View Research).
Ocrevus's market position:
- Currently captures a significant share of the MS biologics segment.
- Competitors include Biogen's Tecfidera and Novartis's Mayzent as oral therapies; other monoclonal antibodies such as Rituxan (off-label use for MS) and Kesimpta.
Key growth drivers:
- Increasing diagnosis rates of MS.
- Expanded label indications for both relapsing and primary progressive forms.
- R&D efforts pushing for longer dosing intervals and combination therapies.
- Market penetration in emerging markets with growing healthcare infrastructure.
Current pricing landscape
Pricing baseline (U.S. retail):
- The average wholesale price (AWP) for Ocrevus is approximately USD 6,800 per infusion.
- Typical dosing schedule:
- 300 mg at baseline, followed by 600 mg every six months.
- Treatment cycle costs around USD 13,600 annually per patient.
Cost factors:
- The drug’s high manufacturing complexity, involving recombinant DNA technology, justifies its premium pricing.
- Payer negotiations and rebate structures result in net prices averaging 10-20% lower than list prices.
Reimbursement environment:
- Medicare Part B covers Ocrevus, with patients liable for coinsurance based on Medicare reimbursement.
- Commercial insurers often negotiate discounts; out-of-pocket costs vary significantly.
Market projections and near-term outlook
| Year |
Estimated Global MS Market (USD billion) |
Ocrevus Market Share |
Ocrevus Sales (USD billion) |
| 2022 |
23.5 |
35% |
8.2 |
| 2023 |
25.4 |
37% |
9.4 |
| 2025 |
30.0 |
40% |
12.0 |
| 2030 |
35.0 |
42% |
14.7 |
Assumptions:
- Market share increase driven by expanded indications and evidence of efficacy in PPMS.
- Price remains stable; however, biosimilar competition could influence prices after patent expiration (anticipated around 2030).
Potential impact of biosimilars:
- Biosimilars for monoclonal antibodies typically enter markets 8-10 years post-approval.
- Initial biosimilars could reduce prices by 20-40%.
- Price erosion expected in advanced markets will influence global pricing strategies.
Pricing evolution and regulatory considerations
Pricing trends:
- Historically, monoclonal antibody prices have increased by 5-10% annually.
- Payer pressure and healthcare reforms aim to moderate increases.
Regulatory shifts:
- The push for biosimilar approval and substitution could lower costs.
- International pricing restrictions and adherence to value-based pricing models shape future prices.
Summary
Ocrevus maintains a premium pricing model with list prices around USD 6,800 per infusion. Its market share in MS continues to grow, supported by increased diagnosis and expanding indications. While current revenue projections anticipate steady growth, biosimilar competition, expected around 2030, could significantly impact pricing and market dynamics.
Key Takeaways
- The global MS drug market is projected to reach USD 35 billion by 2030.
- Ocrevus accounts for roughly 35-40% of MS biologics revenue, with sales predicted to grow at a CAGR of 8%.
- Current list price per infusion is about USD 6,800, with net prices lower due to rebates and negotiated discounts.
- Biosimilars could introduce price reductions of up to 40%, starting around 2030.
- Market growth depends on expanded indications, increased diagnosis rates, and payer acceptance.
FAQs
1. What factors influence Ocrevus pricing?
Manufacturing complexity, market demand, competition, and payer negotiations.
2. How will biosimilars affect Ocrevus sales?
Biosimilars are expected to reduce prices after patent expiry, potentially lowering revenue.
3. What are the primary competitors for Ocrevus?
Tecfidera, Mayzent, Kesimpta, and emerging biologics and oral therapies.
4. How does U.S. reimbursement affect the real-world price?
Price discounts through rebates and negotiated rates for payers reduce patient expenses.
5. Are there upcoming regulatory changes that could impact pricing?
Yes; increased approval of biosimilars and value-based pricing models could influence costs.
References
[1] Grand View Research. Multiple sclerosis (MS) drugs market size, share & trends analysis. 2022.
[2] IQVIA. The Market Outlook for MS treatments, 2022.
[3] U.S. Food and Drug Administration. Ocrevus (ocrelizumab) prescribing information. 2017.
[4] Biotech Eye. Biosimilar market trends for monoclonal antibodies. 2022.
[5] Centers for Medicare & Medicaid Services. Medicare coverage and reimbursement data, 2022.
Please advise if further breakdowns or specific analyses are required.
